文献速递白血病

2022年欧洲白血病网危险分层体系在接受强化化疗的18至65岁新发急性髓系白血病患者中预后意义的验证

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2023-03-13

该研究在809例接受标准化疗的18-65岁新发非M3型急性髓系白血病患者中验证ELN-2022危险分层。106例(13.1%)患者的危险类别较ELN-2017发生重新分类。ELN-2022能有效区分预后良好、中等和不良三组,作者进一步提出的细化体系可区分四组,但需前瞻性验证。

要点

  • ELN-2022在809例18-65岁新发AML患者中可区分预后良好、中等和不良三组。
  • 106例(13.1%)患者按ELN-2022较ELN-2017发生危险类别重新分类。
  • 达到首次完全缓解的中等危险组患者接受异基因移植有益,良好或不良组未见获益。

核心结论

  • ELN-2022有助于将年轻、接受强化治疗的患者分为三组不同结局;作者提出的ELN-2022细化可能进一步改善AML患者的危险分层。
  • 作者指出需对新预测模型进行前瞻性验证。

研究设计与样本

  • 研究纳入809例新发、非M3、年龄18-65岁、接受标准化疗的急性髓系白血病患者,验证ELN-2022的危险分层预后相关性。

主要发现

  • 106例(13.1%)患者的危险类别从ELN-2017重新分类为ELN-2022。
  • ELN-2022在缓解率和生存方面有效区分预后良好、中等和不良危险组。
  • 在达到首次完全缓解(CR1)的患者中,异基因移植对中等危险组有益,但对良好或不良危险组无益。
  • 作者提出的细化体系将t(8;21)(q22;q22.1)/RUNX1::RUNX1T1伴KIT高表达、JAK2或FLT3-ITD高突变患者重新归入中等危险亚组。
  • 作者提出的细化体系将t(7;11)(p15;p15)/NUP98::HOXA9及DNMT3A与FLT3-ITD共突变患者归入不良危险亚组,并将复杂或单体核型、inv(3)(q21.3q26.2)或t(3;3)(q21.3;q26.2)/GATA2,MECOM(EVI1)或TP53突变患者归入极不良危险亚组。

临床怎么用

  • 作者认为,ELN-2022有助于区分年轻、接受强化治疗患者的三个不同结局组。
  • 作者建议的ELN-2022细化可能进一步改善AML患者的危险分层。
  • 作者指出,需对新预测模型进行前瞻性验证。

局限性

  • 原文指出需对新预测模型进行前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European LeukemiaNet (ELN) recently proposed a revised recommendation for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized as ELN-2022. However, validation in a large real-world cohort remains lacking. In this study, we aimed to validate the prognostic relevance of the ELN-2022 in a cohort of 809 de novo, non-M3, younger (ages 18-65 years) AML patients receiving standard chemotherapy. The risk categories of 106 (13.1%) patients were reclassified from that determined using ELN-2017 to that determined using ELN-2022. The ELN-2022 effectively helped distinguish patients as favorable, intermediate, and adverse risk groups in terms of remission rates and survival. Among patients who achieved first complete remission (CR1), allogeneic transplantation was beneficial for those in the intermediate risk group, but not for those in the favorable or adverse risk groups. We further refined the ELN-2022 system by re-categorizing AML patients with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 with KIThigh , JAK2 or FLT3-ITDhigh mutations into the intermediate risk subset, AML patients with t(7;11)(p15;p15)/NUP98::HOXA9 and AML patients with co-mutated DNMT3A and FLT3-ITD into the adverse risk subsets, and AML patients with complex or monosomal karyotypes, inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2,MECOM(EVI1) or TP53 mutation into the very adverse risk subset. The refined ELN-2022 system performed effectively to distinguish patients as favorable, intermediate, adverse, and very adverse risk groups. In conclusion, the ELN-2022 helped distinguish younger, intensively treated patients into three groups with distinct outcomes; the proposed refinement of ELN-2022 may further improve risk stratification among AML patients. Prospective validation of the new predictive model is necessary.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lo MY, Tsai XC, Lin CC, et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023. PMID: 36861732. doi:10.1002/ajh.26892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。